Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib monotherapy for recurrent high-grade glioma
ChiCTR2200056037Phase 2Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in glioma, sponsored by First Hospital of China Medical University. Primary endpoint: 6-month progression-free survival rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2200056037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056037.